Literature DB >> 20164566

Caffeine and adenosine.

Joaquim A Ribeiro1, Ana M Sebastião.   

Abstract

Caffeine causes most of its biological effects via antagonizing all types of adenosine receptors (ARs): A1, A2A, A3, and A2B and, as does adenosine, exerts effects on neurons and glial cells of all brain areas. In consequence, caffeine, when acting as an AR antagonist, is doing the opposite of activation of adenosine receptors due to removal of endogenous adenosinergic tonus. Besides AR antagonism, xanthines, including caffeine, have other biological actions: they inhibit phosphodiesterases (PDEs) (e.g., PDE1, PDE4, PDE5), promote calcium release from intracellular stores, and interfere with GABA-A receptors. Caffeine, through antagonism of ARs, affects brain functions such as sleep, cognition, learning, and memory, and modifies brain dysfunctions and diseases: Alzheimer's disease, Parkinson's disease, Huntington's disease, Epilepsy, Pain/Migraine, Depression, Schizophrenia. In conclusion, targeting approaches that involve ARs will enhance the possibilities to correct brain dysfunctions, via the universally consumed substance that is caffeine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164566     DOI: 10.3233/JAD-2010-1379

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  114 in total

1.  Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Δ9-tetrahydrocannabinol on spatial memory.

Authors:  Vasco C Sousa; Natália Assaife-Lopes; Joaquim A Ribeiro; Judith A Pratt; Ros R Brett; Ana M Sebastião
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

2.  Molecular mechanisms of caffeine-mediated intestinal epithelial ion transports.

Authors:  Fenglian Zhang; Hanxing Wan; Xin Yang; Jialin He; Cheng Lu; Shiming Yang; Biguang Tuo; Hui Dong
Journal:  Br J Pharmacol       Date:  2019-04-11       Impact factor: 8.739

3.  Caffeine intake and cognitive functions in children.

Authors:  Han Zhang; Zu Xuan Lee; Anqi Qiu
Journal:  Psychopharmacology (Berl)       Date:  2020-06-29       Impact factor: 4.530

Review 4.  Purines and neuronal excitability: links to the ketogenic diet.

Authors:  S A Masino; M Kawamura; D N Ruskin; J D Geiger; D Boison
Journal:  Epilepsy Res       Date:  2011-08-30       Impact factor: 3.045

5.  Hindbrain cytoglucopenia-induced increases in systemic blood glucose levels by 2-deoxyglucose depend on intact astrocytes and adenosine release.

Authors:  Richard C Rogers; Sue Ritter; Gerlinda E Hermann
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-04-13       Impact factor: 3.619

6.  Caffeine exposure ameliorates acute ischemic cell death in avian developing retina.

Authors:  D Pereira-Figueiredo; R Brito; D S M Araújo; A A Nascimento; E S B Lyra; A M S S Cheibub; A D Pereira Netto; A L M Ventura; R Paes-de-Carvalho; K C Calaza
Journal:  Purinergic Signal       Date:  2020-02-20       Impact factor: 3.765

Review 7.  Adenosine and autism: a spectrum of opportunities.

Authors:  Susan A Masino; Masahito Kawamura; Jessica L Cote; Rebecca B Williams; David N Ruskin
Journal:  Neuropharmacology       Date:  2012-08-24       Impact factor: 5.250

Review 8.  Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.

Authors:  A J Carman; P A Dacks; R F Lane; D W Shineman; H M Fillit
Journal:  J Nutr Health Aging       Date:  2014-04       Impact factor: 4.075

9.  Caffeine Prevents Memory Impairment Induced by Hyperhomocysteinemia.

Authors:  Karem H Alzoubi; Nizar M Mhaidat; Emad A Obaid; Omar F Khabour
Journal:  J Mol Neurosci       Date:  2018-08-23       Impact factor: 3.444

10.  Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.

Authors:  Maria Garrido; Jelena Skorucak; Daniela Raduazzo; Matteo Turco; Giuseppe Spinelli; Paolo Angeli; Piero Amodio; Peter Achermann; Sara Montagnese
Journal:  Metab Brain Dis       Date:  2016-05-19       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.